

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number
WO 2023/034923 A9

(43) International Publication Date
09 March 2023 (09.03.2023)

(51) International Patent Classification:

C07K 16/30 (2006.01) A61K 39/395 (2006.01)

(21) International Application Number:

PCT/US2022/075847

(22) International Filing Date:

01 September 2022 (01.09.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/240,404 03 September 2021 (03.09.2021) US

(71) Applicant: NOVAROCK BIOTHERAPEUTICS, LTD.

[US/US]; 801 Charles Ewing Blvd., Ewing, New Jersey 08628 (US).

(72) Inventors: PEI, Yi; 1836 Glenwold Drive, Paoli, New

Jersey 19301 (US). HUANG, Haichun; 4329 Crestwood Street, Fremont, California 94538 (US). LOI, Yick; 23 Windsor Drive, East Brunswick, New Jersey 08816 (US). CHEN, Chang Hung; 13623 Palmetto Circle, Germantown, Maryland 20874 (US). LI, Han; 1 Claire Dr., Newtown, Pennsylvania 18940 (US). SHEN, Di; 119 Bedford Ct, Piscataway, New Jersey 08854 (US). LEI, Ming; 20 Lockwood Drive, Princeton, New Jersey 08540 (US).

(74) Agent: MORGAN, LEWIS & BOCKIUS LLP; 110

North Wacker Drive, Suite 2800, Chicago, Illinois 60606 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))

(48) Date of publication of this corrected version:

11 May 2023 (11.05.2023)

(15) Information about Correction:

see Notice of 11 May 2023 (11.05.2023)

(54) Title: BISPECIFIC AND TRISPECIFIC BINDING PROTEINS TO PD-L1, CD137, AND/OR TGF β AND USES THEREOF

(57) Abstract: The disclosure provides binding proteins that bind PD-L1 and CD137 (PD-L1/CD137 bispecific), binding proteins that bind PD-L1 and TGF β (PD-L1/TGF β bispecific), binding proteins that bind PD-L1, TGF β , and CD137 (PD-L1/TGF β /CD137 trispecific), and binding proteins that bind CD137, TGF β , and PD-L1 (CD137/TGF β /PD-L1 trispecific). The disclosure also provides pharmaceutical compositions comprising these binding proteins, and methods of their use to treat and/or prevent cancer.



WO 2023/034923 A9